Skip to Navigation Skip to Search Skip to Content
Search All Centers

What Patient Subset Will Novel Lung Cancer Treatments Work Best For?

Read Transcript Download/Print Transcript

Published on August 6, 2018

As the treatment landscape for lung cancer continues to evolve, will novel approaches apply to a wide subset of patients? Renowned expert Dr. Jeffrey Crawford explains what factors go into making treatment decisions for patients with a history of smoking and shares statistics on how this patient population is typically affected by the genetic mutations EGFR, ALK and PD-L1. Dr. Crawford also discusses why molecular testing is critical before starting therapy. 

This is a Patient Empowerment Network program produced by Patient Power. We thank Celgene and Pfizer for their support.

Featuring

Sponsors

Patient Empowerment Network

You might also like

Transcript | What Patient Subset Will Novel Lung Cancer Treatments Work Best For?

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

You might also like